morbidity or mortality. Shorter emLOS (POD 4 vs. POD 7; p = 0.018), earlier resumption of sufficient oral intake (POD 3 vs. POD 4; p = 0.034) and faster recovery to defecation (2.2 vs. 3.1 days; p = 0.005) were observed in the ED group vs. the control group. Conclusions The perioperative ingestion of ED by patients undergoing laparoscopic colectomy is safe and can reduce the postoperative hospital stay by supporting the acceleration of oral intake.
Introduction
Over the past 10 years, it has become generally accepted that perioperative nutritional management enhances outcomes after surgery. For elective surgery, fasting prior to
Abstract
Purpose An amino acid-containing elemental diet (ED) does not require digestion for nutritional absorption, making it a good option for patients with gastrointestinal malabsorption. We conducted a randomized trial to confirm that perioperative ED enhanced the recovery of patients undergoing laparoscopic colectomy. Methods Patients in the intervention arm received commercially available ED from the day prior to surgery until postoperative day (POD) 3, whereas patients in the control group received a conventional perioperative diet program. To verify the endpoints, "estimated minimum length of stay in hospital after surgery" (emLOS) was defined as the number of days necessary to reach all the five criteria; namely, "sufficient oral intake", "sufficient pain control", "withdrawal of intravenous alimentation", "no abnormal findings in routine examinations", and "no rise in fever". Results A total of 102 patients were randomized, 94 of whom were analyzed (ED 45, control 49). There was no anesthesia is now limited to 6 h for solids and 2 h for clear carbohydrate drinks (CCD) [1, 2] . For postoperative oral intake after laparoscopic colectomy, the Enhanced Recovery After Surgery (ERAS ® ) protocol recommends oral intake at the earliest possible opportunity [3] .
Despite the interest in perioperative nutritional management, adequate discussions concerning optimal nutrient composition have yet to take place. To investigate an alternative perioperative nutritional management protocol for preoperative CCD ingestion and postoperative intake of oral nutritional supplements (ONS), we used a commercially available elemental diet (ED), Elental ® (EA Pharma Co., Ltd., Tokyo, Japan) for this study. The composition of solution-prepared Elental ® is 1 kcal/ml, 906 mOsm/kg, and a 300 ml solution (1 package) contains 63.41 g carbohydrates (provided as dextrin), 13.14 g amino acids (provided as 17 amino acids including 9 essential amino acids), 0.51 g of fat, and vitamins and minerals. This amino acid-containing high-calorie and low-fat ED has high nutritional absorbency without requiring digestion. Therefore, it is recommended for digestive diseases [4] such as inflammatory bowel disease, acute pancreatitis, and short bowel syndrome. Based on the fact that ED does not require digestion for absorption, we hypothesized that perioperative nutritional management with ED would be beneficial for patients suffering postoperative insufficiency of digestive function [5] . Furthermore, we expected that the lower fat content of ED would not interfere with the clearance of the solution from the stomach and would be suitable for preoperative ingestion. Consequently, we designed a randomized controlled trial (RCT) to establish whether the ingestion of perioperative ED accelerates the return of gastrointestinal function and promotes recovery in patients undergoing laparoscopic colectomy.
Methods

Study design
The protocol for this clinical trial, "Multicenter study of the effect of elemental diet for perioperative nutrition in laparoscopic colorectal surgery (EPLAS)", was approved by the Ethics Committee of the Hokkaido University Graduate School of Medicine (IRB#011-0249) and registered on the UMIN Clinical Trials Registry (#000008154). The study was carried out by Gastroenterological Surgery II, Hokkaido University Hospital and ten affiliated hospitals; namely, Sapporo Tonan Hospital KKR Medical Center, Hokkaido Gastroenterology Hospital, Obihiro-Kosei General Hospital, Steel Memorial Muroran Hospital, Japanese Red Cross Kitami Hospital, Hakodate Central General Hospital, Oji General Hospital, NTT East Sapporo Hospital, Japanese Red Cross Asahikawa Hospital, and Kushiro City General Hospital. Ethics committee approval was given by all the centers, and the trial was conducted based on ethical guidelines for clinical studies, taking into consideration the patients' human rights and privacy.
Patient eligibility
Patients meeting all of the following criteria were selected as subjects for this study: diagnosed colorectal cancer located in the colon and the rectosigmoid, planned laparoscopic surgery, histologically proven colorectal adenocarcinoma, expectation of a curative operation regardless of the stage of the cancer, sufficient physical function of the main organs, under 76 years of age, performance status (ECOG) [6] of 0 or 1, and voluntary written informed consent. Initial exclusion criteria were as follows: neoplastic symptoms of intestinal obstruction; anemia caused by tumor bleeding or perforation of the tumor; preoperative chemotherapy, radiotherapy, or immunotherapy; severe or uncontrolled complications; risk of aspiration pneumonia related to neurological or neuromuscular disease; psychosis or psychiatric disorders judged by the investigator as disqualifying the patient from participating in the study; and any other reasons warranting non-inclusion. Exclusion criteria after initial registration and randomization were as follows: withdrawal by the patient, changes in the planned operative procedure such as conversion to open surgery, and any other reasons judged by the investigators as necessitating exclusion from the study.
Interventions
Patients in the intervention arm (ED group) were given Elental ® , using the following protocol: On the day prior to surgery, patients were instructed to drink perioperative ED 900 mL with a bowel preparation diet. On the day of surgery, they were instructed to drink 300 ml, completed 2.5 h before transportation to the operating room, and 300 ml postoperatively, commencing 5 h after operation and when the patient was able to sit up. On postoperative day (POD) 1 and 2, they were instructed to drink 900 mL/day and on POD 3, they were instructed to drink 300-900 mL with the start of dietary intake of hospital food.
Patients in the control group received a conventional perioperative diet program ( Table 1 ). The preoperative bowel preparation was the same in each group and consisted of 0.75 % sodium picosulfate and sennosides, ingested orally.
Endpoints, sample size, and randomization
The primary endpoint was the ratio of patients who achieved an "estimated minimum length of stay in hospital after surgery" (emLOS) of less than 1 week, defined as the number of days required to fulfill all five criteria for discharge; namely, "sufficient oral intake", "sufficient pain control", "withdrawal of intravenous alimentation", "no abnormal findings in routine examinations", and "no rise in fever". "Sufficient oral intake" was defined as regular hospital food accounting for over 80 % of oral intake. "Sufficient pain control" was defined as the withdrawal of epidural anesthesia and a subjective pain scale of 0 or 1 (0: "painless", 1: "slight", 2: "moderate", 3: "severe," 4: "worst") regardless of the use of oral analgesic medication. "No abnormal findings in routine examinations" was defined as postoperative laboratory data (WBC, Plt, Hb, TP, Alb, T-Bil, AST, ALT, Cr, and CRP) within the normal range for each institution or recovery of the postoperative data to the preoperative reference values of each patient as judged by the attending surgeon, and the absence of abnormal X-ray findings such as ileus or pneumonia. "No rise in fever" was defined as a body temperature lower than 38 °C or equivalent to the patient's baseline. The secondary outcomes were safety, compliance of perioperative administration of ED, adverse events and complications, and length of stay in hospital after surgery (LOS). Subjective items such as pain scale and nausea were self-reported by patients, using survey sheets and monitored by the attending nurses. Stool features were categorized on the survey sheets in check boxes as 'diarrhea', 'soft feces', 'normal feces', and 'hard feces' and self-reported by patients. Routine perioperative examinations were scheduled at four points: preoperatively, then on PODs 1, 4, and 7. The sample size setting was based on the results of a small scale pilot study undertaken by our group (unpublished data). According to this study, the emLOS within POD 7 for each group was hypothesized as 80 % for the ED group and 50 % for the control group, respectively. To predict a clinically relevant emLOS within POD 7 (80 % test power and α level of 0.05), 78 patients were required based on a power calculation. To allow for dropouts we planned to recruit 50 patients in each group. Random allocations performed by an independent statistician were completed before the surgery, using the minimization method to balance institution, sex, age, and location of the tumor.
Statistical analysis
Patients were analyzed according to intention-to-treat principles. StatFlex ver.6 software (Osaka, Japan) and JMP Pro11 software (Tokyo, Japan) were used for the statistical analysis. Continuous, normally distributed data were expressed as mean ± SD, and statistical analysis was performed using an unpaired t test. Non-normally distributed data were expressed as median values (maximum-minimum range) and the Mann-Whitney U test was used. Fisher's exact test was used for categorical data. The p values presented are two tailed and p < 0.050 was considered significant.
Results
Out of a total 102 patients recruited and randomized, 94 were analyzed after the exclusion of 8 (Fig. 1) . There was no difference between the groups in baseline variables, clinical findings, or perioperative data ( Table 2) .
"Estimated minimum length of stay in hospital after surgery" and actual LOS Table 3 summarizes the clinical outcomes of emLOS, the criteria of discharge, and the actual LOS for each group. The median number of days to achieve emLOS was significantly shorter in the ED group than in the control group (POD 4 vs. POD 7, p = 0.018). "Sufficient oral intake" was established on POD 3 in the ED group and on POD 4 in the control group (p = 0.034). The significance of "withdrawal of intravenous alimentation" (p = 0.019) resulted from ED 300-900 mL PPN 1000 mL POD 4 ~+Rice gruel (medium-solid) ~ normal diet the different intravenous alimentation schedules within 3 PODs (Table 1 ). The median actual LOS was not significantly different between the groups, at 9 vs. 10 days for the ED group and the control group, respectively (p = 0.176). Figure 2 shows the time-course for achieving emLOS in each group. The primary endpoint for the ratio of patients who achieved an emLOS of less than 1 week was not significant; however, the ratio of patients who achieved the criteria on POD 4 was significantly higher in the ED group (51 vs. 29 %, p = 0.035), whereas no significant difference was observed after this period. Figure 3 shows the time-course of oral intake of the meals supplied to each group. The ED group reached 80 % oral intake on POD 3, whereas the control group took 4 days to reach the same level. A significant difference was observed on POD 5 (100 vs. 80 %, p = 0.025).
Adverse events and gut function outcomes
Postoperative morbidity was comparable in the two groups (Table 4) . Table 5 summarizes the outcomes of gut function. Defecation occurred significantly earlier in the ED group than in the control group (2.2 ± 1.6 vs. 3.1 ± 1.6, respectively; p = 0.005). Postoperative digestive symptoms, including diarrhea, nausea, and vomiting during administration of the elemental diet from the day of the surgery to POD 3 in the ED group were not significantly different from those seen in the control group (Table 5) .
Compliance of the elemental diet
The percentage of patients who adhered to the protocol was 44 % in the ED group. Twenty-five patients were protocolvariant, 12 of whom continued on daily ED at a reduced volume. The percentage of patients who ingested at least half the volume of ED of the protocoled dose during the protocol period was 65 % (Table 6 ).
Discussion
The length of stay in hospital after surgery varies in each country according to social conditions such as medical insurance systems and cultural factors [7] . According to a report based on a nation-wide clinical trial, the postoperative hospital stay after laparoscopic surgery in Japan is generally 10 days [8] . Although recent studies demonstrate a shorter hospital stay achieved by single-incisional laparoscopic surgery [9, 10] , in this study, no advantage in the length of stay in hospital after surgery was evident for the five patients who underwent single incision laparoscopic surgery (two patients in the ED group and three in the control group; Table 2 ).
To assess the benefit of perioperative ED ingestion to a patient's recovery, we defined the criteria of emLOS to indicate the hypothetical minimal length of stay after surgery for each patient. The emLOS represents the number of postoperative days required to fulfill all five of the criteria: "sufficient oral intake", "sufficient pain control", "withdrawal of intravenous alimentation", "no abnormal findings in routine examinations", and "no rise in fever". These criteria are used to decide when to discharge a In this study, we noted a significant difference in the emLOS between the groups, as an indicator of recovery after surgery, although the actual LOS did not differ significantly. Two recent reports by Fiore et al. [11, 12] present their criteria for hospital discharge following colorectal surgery using both the Delphi technique and systemic review. These criteria are oral intake, recovery of the lower gastrointestinal function, adequate pain control, adequate mobility, and absence of evidence of complications or untreated medical problems. The emLOS covers all these criteria except mobility. To improve the emLOS as a more precise criterion, simple and objective index measures of a patient's mobility such as "no requirement for nursing care to assist with dietary intake, excretion, dressings, and showering" should be added as components of the assessment. Although the safety of 2-h fasting after the ingestion of CCD prior to the induction of anesthesia is based on the knowledge that CCD is less retained within the stomach [1, 2] , the length of fasting after the administration of amino acids is controversial. Lobo et al. [13] reported that ONS containing 15 g of glutamine with 50 g carbohydrate dissolved in water to a total volume of 300 or 400 ml prolonged gastric empting considerably more than 400 ml of standard CCD (preOp ® ) containing an equal weight of carbohydrates, and recommended at least 3-h preoperative fasting for protein or fat containing clear liquids. Awad et al. [14] compared three isocaloric-isovolumetric (410 ml and 207kCal) solutions; namely, standard CCD (preOp ® ), amino-acid-containing solution (36 g carbohydrate + 15 g glutamine), and lipid-containing solution (36 g carbohydrate + 7 g lipid). Their study demonstrated that glutamine and lipid supplementation did not prolong gastric emptying and that the glutamine-containing supplement reduced the glucose response more than the others. Gastric emptying of Elental ® is known to be faster than that of standard ONS [15] , but as the actual clearance time from the stomach was never examined, we conducted a pilot study to confirm the safety of ED ingestion. Clearance from the stomach was confirmed in three healthy volunteers by endoscopic evidence of the absence of residual liquid within the stomach 2.5-3 h after the oral ingestion of 300 ml. Based on this result, we decided on the protocol of 2.5 h fasting after the ingestion of ED prior to transportation to the operating room and no adverse events concerning the safety of ED ingestion were observed in this study. Moreover, there were no ED-related preoperative adverse events or incidents during the induction of anesthesia. Anastomotic leakage occurred only in the control group, as two cases of Grade II and one case of Grade IIIb leakage, according to the JCOG postoperative complication criteria based on the Clavien-Dindo classification [16, 17] , whereas bleeding occurred only in the ED group (Table 4) . Minor anastomotic bleeding events (Grade I and II, respectively) were observed on the day of surgery and on POD 1 after the postoperative or preoperative ingestion of 300 ml of ED, respectively, and these events did not influence the postoperative course. Accordingly, we decided that the bleeding event was not likely to have been caused by the intervention, but by other factors such as the stapling technique. The incidence of postoperative vomiting and ileus did not differ significantly between the groups (Tables 4, 5 ). We conclude that the preoperative ingestion of 300 ml of this ED, Elental ® , not less than 2.5 h prior to anesthesia, was safely accepted by patients in a normal physical condition. However, the clinical application of preoperative oral ED should only be carried out understanding the limitations of this RCT, which did not evaluate actual clearance of the ED solution from the stomach in cancer patients or define the safety of ED ingestion by patients in a poor condition.
Compliance to the protocol is another issue, as only 44 % of the patients in the ED Group adhered to the protocol (Table 6) . Although almost all patients complied with the protocol before surgery, only about the half of these adhered to the postoperative ED-ingestion schedule, which could be attributed to the taste or volume of the solution and the development of diarrhea. Although the incidence of diarrhea in this study was not significantly different between the groups, at 51 % in the ED group vs. 31 % in the control group (p = 0.059), this might have been high enough for the medical staff or patient to reduce the volume of ED ingested. Therefore, to develop the postoperative ingestion program of ED in clinical practice, optimizing the volume and concentration of the solution to minimize diarrhea is necessary to keep patients on ED.
The major limitation of this study, apart from its open label design, is the validity of the hypothesis for the endpoint. The primary endpoint was not significant, although some secondary endpoints showed the benefits of ED. The primary endpoint we had set was the rate of emLOS achievement by POD 7, based on the hypothesis that ED would promote approximately 30 % improvement (hypothesis; ED 80 %, Control 50 %). Contrary to the result of the pilot study, both groups achieved over 80 % (Fig. 2) . The most probable cause is not related to the issues concerned with the implementation of the study, but to the initial study design. An inaccurate setting of the primary endpoint deduced from a small-scale pilot study in a single institution might explain this.
Further research is necessary to establish the true value of ED as a perioperative supplemental feeding option. This study was not designed based on the ERAS ® protocol [3] ; accordingly, the results of the RCT left some questions unanswered: was the laxative effect observed in the intervention group Elental-specific or would other ONSs have the same effect? Did the different peripheral parenteral nutrition schedules in the two groups affect the clinical outcomes? To resolve these questions and to evaluate the advantage of the perioperative ingestion of ED, we must compare the perioperative use of ED with the combined use of preoperative CDC and postoperative ONS, on applying the latest ERAS protocol to both arms. This study was not designed to assess metabolic data (such as elevation of the blood glucose level, insulin response, or nitrogen balance) and muscle strength after the perioperative administration of ED, which have already been proven by the ingestion of CCD [18] [19] [20] [21] . Recent studies have argued in favor of perioperative ONS with "enhancing" specific amino acids administration such as glutamine to improve the cumulative nitrogen balance and decrease postoperative infectious morbidity [22] . The merit or necessity of ED as "all-inclusive" nutritional elements over ONSs "enhancing" specific amino acids requires further research.
In conclusion, this study is the first RCT that investigates the perioperative ingestion of ED in laparoscopic colectomy. Based on our findings, the perioperative ingestion of ED is safe and may shorten postoperative hospital stay by helping accelerate bowel movement and promoting postoperative feeding. To confirm the advantages of perioperative ED vs. both preoperative CCD and early feeding with supplemental ONS, further investigation through a well-designed RCT is necessary.
